Breaks Categories: News

ThursdayNov 12, 2020 12:43 pm

PsychedelicNewsBreaks – Rritual Receives USDA Organic Certification, Official Confirmation of Product Quality

Rritual announced that it has received the United States Department of Agriculture (“USDA”) Organic Certification. Awarded only after a demanding vetting process, the seal confirms the high quality of Rritual’s product lineup and manufacturing process. Rritual launched its original product lineup in September, which features products formulated with mindfully selected functional mushrooms and adaptogenic herbs. The products are designed to help relieve stress, improve cognitive function and support the immune system. As a Certified Organic company, Rritual meets a strict process that verifies its ingredients are free from antibiotics, toxic pesticides, synthetic hormones and genetically modified organisms (“GMOs”). In addition, Rritual…

Continue Reading

WednesdayNov 11, 2020 10:21 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) Goes Public on Canada’s Next-Gen Stock Exchange

Cybin (NEO: CYBN), a leading Toronto-based biotech and life sciences company focused on psychedelic pharmaceutical therapies, today made its debut on the global public markets and is now trading on the NEO Exchange under the symbol “CYBN.” The company, which focuses on psychedelic drug development, unique delivery mechanisms, improved novel compounds and protocols, recently closed a C$45 million subscription receipt financing in relation to its reverse takeover transaction. This signified the largest subscription receipt financing in the Canadian psychedelic sector. “Today marks a meaningful milestone for our company, as our shares begin trading on the NEO Exchange under the ticker…

Continue Reading

FridayNov 06, 2020 11:16 am

PsychedelicNewsBreaks – CYBIN Inc. Completes Reverse Takeover Transaction

CYBIN (formerly Clarmin Explorations Inc.), a life sciences company initially focused on psychedelic pharmaceutical therapies, on Thursday announced it has completed its previously disclosed reverse takeover of Clarmin Explorations Inc. per the terms of an amalgamation agreement dated June 26, 2020, as amended on October 21, 2020. The agreement was among Cybin Corp., Clarmin and 2762898 Ontario Inc. (“SubCo”), a wholly-owned subsidiary of the company (the “reverse takeover”), in which the reverse takeover was completed by way of a “three-cornered” amalgamation pursuant to the provisions of the Business Corporations Act (Ontario). Through the reverse takeover, Cybin Corp. amalgamated with SubCo…

Continue Reading

ThursdayNov 05, 2020 10:24 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) Commences CSE Trading

Pure Extracts Technologies (CSE: PULL), a plant-based extraction company focused on cannabis, hemp, and functional mushroom sectors, today announced that, effective immediately, the company’s stock has commenced trading on the Canadian Securities Exchange (“CSE”) under the symbol “PULL.” “There currently is a tremendous consumer demand for natural health products with the ability to immediately enhance our quality of life. With Health Canada officially granting Pure Extracts a Standard Processing License under the Cannabis Act, this has put us on a path to deliver full-spectrum oil products by the end of Q4, 2020,” PULL CEO Ben Nikolaevsky said in a recent…

Continue Reading

FridayOct 30, 2020 1:35 pm

PsychedelicNewsBreaks – Rritual Mushrooms Inc. Recognized at ECRM’s Whole Body & Mind Wellness Program

Rritual, a plant-based consumer wellness brand, was selected as runner up for the Buyers Choice Award at last week’s virtual ECRM program. According to an article on Business Wire, Rritual’s Reishi Relax Elixir was selected for the award among dozens of entries evaluated by retail buyers. “Retail buyers selected Rritual for the award because our packaging, design and formulation stood out amongst the dozens of products they evaluated,” said David Kerbel, CEO of Rritual. “Their stamp of approval on our product reinforces what we know: that Rritual products will capture the attention of shoppers on shelves and in e-comm, supporting…

Continue Reading

ThursdayOct 29, 2020 12:34 pm

PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF) Addresses Continuous Disclosure Review

Champignon Brands (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF) has provided an update on its efforts to resolve a continuous disclosure review that was issued earlier this year. Champignon is working closely with the British Columbia Securities Commission (“BCSC”) to coordinate the revocation of the cease trade order and hopes to provide information about a revocation of the order as soon as possible. In the update, the company noted that it has submitted all documentation requested by the BCSC in connection with the review of financial statements of AltMed Capital Corp. ("AltMed") for the period ended June 30, 2020. The purpose of the…

Continue Reading

WednesdayOct 07, 2020 11:25 am

PsychedelicNewsBreaks – Rritual Mushrooms Inc. Engages InvestorBrandNetwork

Rritual Mushrooms, a premium brand in the emerging functional mushroom market, has announced that it has selected InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, for its communication needs. Founded in 2019, Rritual Mushrooms is a private company with a declared purpose to help people meet the demands of modern life with style and ease by incorporating functional mushrooms, adaptogens and superfoods into their diets. Rritual Mushrooms engaged IBN to leverage its investor-based distribution network of more than 5,000 key syndication outlets, social media channels, wire services and more to tell the Rritual story. That story includes Rritual’s ability to…

Continue Reading

MondayOct 05, 2020 10:54 am

PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Elects Leading International Expert as Board Chairman

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), today announced the election of Dr. Roger McIntyre as chairman of its board of directors. A foremost international expert in depression and suicide, Dr. McIntyre is a professor of Psychiatry and Pharmacology at the University of Toronto, heads the Mood Disorders Unit at the University Health Network in Toronto and holds appointments among scientific and clinical organizations across the United States and Asia. Dr. McIntyre was appointed to Champignon’s board in July 2020 and assumed the role of CEO in May 2020. He has set a strategic direction for the business, which…

Continue Reading

TuesdaySep 15, 2020 3:06 pm

PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Issues Update Regarding Ongoing Disclosure Review

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) continues to work with the British Columbia Securities Commission to address an ongoing continuous disclosure review. According to the update, the company has arranged for the following since the review commenced: Filing of business acquisition reports in connection with the acquisitions of Artisan Growers Ltd., Novo Formulations Ltd. and Tassili Life Sciences Corp.; revocation of the initial cease trade order issued by the Commission on June 19, 2020; preparation of financial disclosure in connection with the acquisition of AltMed Capital Corp. (“AltMed”). The company expects this work to be concluded shortly, as…

Continue Reading

TuesdaySep 15, 2020 12:28 pm

PsychedelicNewsBreaks – Cybin Corp. CEO Discusses Milestones, Goals and Momentum in Exciting Emerging Industry

Cybin, a life-sciences company focused on advancing psychedelic and nutraceutical-based products, today announced that its CEO, Doug Drysdale, is featured in an exclusive audio interview with NetworkNewsWire (“NNW”) – a financial news and content distribution company and one of 50+ brands in the InvestorBrandNetwork (“IBN”). During the interview, Drysdale provides insight into Cybin’s 2020 milestones, near-term goals and its efforts to build on the momentum of an industry that continues to ramp up. “We have secured a source of GMP psilocybin API to support our initial clinical program, and we’ve initiated a program to synthesize our own proprietary API to…

Continue Reading